The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Diabetes India has announced a nationwide campaign for early detection of Chronic Kidney Disease (CKD) in diabetes patients.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.